{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:56:57Z","timestamp":1792792617200,"version":"4.5.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:00:00Z","timestamp":1766534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK","award":["GSK 205715\/NCT02924688"],"award-info":[{"award-number":["GSK 205715\/NCT02924688"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s12325-025-03442-x","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:01:05Z","timestamp":1766563265000},"page":"729-749","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluating Asthma Clinical Remission with Inhaled Therapy: Post Hoc Analyses of CAPTAIN"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct02924688","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"John","family":"Oppenheimer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Pavord","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Corbridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodie","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Gould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hamouda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Howarth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmeline","family":"Burrows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen G.","family":"Noorduyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Slade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,24]]},"reference":[{"key":"3442_CR1","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2025. https:\/\/ginasthma.org\/2025-gina-strategy-report\/. Accessed 11 June 2025."},{"issue":"10258","key":"3442_CR2","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","volume":"396","author":"GBD Diseases and Injuries Collaborators","year":"2020","unstructured":"GBD Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204\u201322.","journal-title":"Lancet"},{"issue":"4","key":"3442_CR3","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.anai.2020.12.015","volume":"126","author":"J Oppenheimer","year":"2021","unstructured":"Oppenheimer J, Slade DJ, Hahn BA, et al. Real-world evidence: Patient views on asthma in respiratory specialist clinics in America. Ann Allergy Asthma Immunol. 2021;126(4):385-393e2.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3442_CR4","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2019-000534","volume":"7","author":"LK Lee","year":"2020","unstructured":"Lee LK, Ramakrishnan K, Safioti G, Ariely R, Schatz M. Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma. BMJ Open Respir Res. 2020;7(1):e000534. https:\/\/doi.org\/10.1136\/bmjresp-2019-000534.","journal-title":"BMJ Open Respir Res"},{"issue":"1","key":"3442_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-017-0014-1","volume":"27","author":"ID Pavord","year":"2017","unstructured":"Pavord ID, Mathieson N, Scowcroft A, et al. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting beta(2)-agonists in the United Kingdom: a cross-sectional analysis. NPJ Prim Care Respir Med. 2017;27(1):17.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"1","key":"3442_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41533-023-00336-9","volume":"33","author":"S Zhang","year":"2023","unstructured":"Zhang S, White J, Hunter AG, et al. Suboptimally controlled asthma in patients treated with inhaled ICS\/LABA: prevalence, risk factors, and outcomes. NPJ Prim Care Respir Med. 2023;33(1):19.","journal-title":"NPJ Prim Care Respir Med"},{"issue":"7","key":"3442_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/thorax-2021-217032","volume":"78","author":"S Soremekun","year":"2023","unstructured":"Soremekun S, Heaney LG, Skinner D, et al. Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study. Thorax. 2023;78(7):643\u201352.","journal-title":"Thorax"},{"key":"3442_CR8","doi-asserted-by":"crossref","unstructured":"International consensus report on diagnosis and treatment of asthma. National Heart, Lung, and Blood Institute, National Institutes of Health. Bethesda, Maryland 20892. Publication no. 92-3091, March 1992. Eur Respir J. 1992;5(5):601\u201341.","DOI":"10.1183\/09031936.93.05050601"},{"key":"3442_CR9","doi-asserted-by":"crossref","unstructured":"National Asthma, Education and Prevention Program. Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol. 2007;120(5 Suppl):S94\u2013138.","DOI":"10.1016\/j.jaci.2007.09.029"},{"key":"3442_CR10","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2006. https:\/\/ginasthma.org\/archived-reports\/. Accessed 14 May 2024."},{"issue":"8","key":"3442_CR11","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1164\/rccm.200401-033OC","volume":"170","author":"ED Bateman","year":"2004","unstructured":"Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170(8):836\u201344.","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"3442_CR12","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/02770903.2018.1455858","volume":"56","author":"J Davis","year":"2019","unstructured":"Davis J, Trudo F, Siddall J, Small M. Burden of asthma among patients adherent to ICS\/LABA: a real-world study. J Asthma. 2019;56(3):332\u201340. https:\/\/doi.org\/10.1080\/02770903.2018.1455858.","journal-title":"J Asthma"},{"issue":"4","key":"3442_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.resinv.2021.02.003","volume":"59","author":"Y Gon","year":"2021","unstructured":"Gon Y, Ohyanagi N, Kobayashi A. The association between control level and self-reported treatment adherence across different treatment types in Japanese asthma patients. Respir Investig. 2021;59(4):454\u201363. https:\/\/doi.org\/10.1016\/j.resinv.2021.02.003.","journal-title":"Respir Investig"},{"issue":"7","key":"3442_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","volume":"4","author":"HG Ortega","year":"2016","unstructured":"Ortega HG, Yancey SW, Mayer B, Gunsoy NB, Keene ON, Bleecker ER, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016;4(7):549\u201356. https:\/\/doi.org\/10.1016\/S2213-2600(16)30031-5.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"3442_CR15","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157\u201371.","journal-title":"N Engl J Med"},{"issue":"2","key":"3442_CR16","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","volume":"158","author":"JE Kavanagh","year":"2020","unstructured":"Kavanagh JE, d\u2019Ancona G, Elstad M, et al. Real-world effectiveness and the characteristics of a \u201cSuper-Responder\u201d to Mepolizumab in severe eosinophilic asthma. Chest. 2020;158(2):491\u2013500.","journal-title":"Chest"},{"issue":"12","key":"3442_CR17","doi-asserted-by":"publisher","first-page":"3650","DOI":"10.1016\/j.jaip.2023.07.024","volume":"11","author":"MC Liu","year":"2023","unstructured":"Liu MC, Bagnasco D, Matucci A, et al. Mepolizumab in patients with severe asthma and comorbidities: 1-year REALITI-A analysis. J Allergy Clin Immunol Pract. 2023;11(12):3650-3661e3.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3442_CR18","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landewe RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3442_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1136\/ard.2011.149765","volume":"70","author":"DT Felson","year":"2011","unstructured":"Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LHD, Funovits J, et al. American College of Rheumatology\/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis. 2011;70(3):404\u201313. https:\/\/doi.org\/10.1136\/ard.2011.149765.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"3442_CR20","volume":"77","author":"M Lommatzsch","year":"2023","unstructured":"Lommatzsch M, Criee CP, de Jong CCM, et al. [Diagnosis and treatment of asthma: a guideline for respiratory specialists 2023\u2014published by the German Respiratory Society (DGP) e. V.]. Pneumologie. 2023;77(8):e3.","journal-title":"Pneumologie"},{"issue":"6","key":"3442_CR21","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.anai.2023.08.609","volume":"131","author":"M Blaiss","year":"2023","unstructured":"Blaiss M, Oppenheimer J, Corbett M, Bacharier L, Bernstein J, Carr T, et al. Consensus of an American College of Allergy, Asthma, and Immunology, American Academy of Allergy, Asthma, and Immunology, and American Thoracic Society workgroup on definition of clinical remission in asthma on treatment. Ann Allergy Asthma Immunol. 2023;131(6):782\u20135. https:\/\/doi.org\/10.1016\/j.anai.2023.08.609.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"3","key":"3442_CR22","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","volume":"145","author":"A Menzies-Gow","year":"2020","unstructured":"Menzies-Gow A, Bafadhel M, Busse WW, Casale TB, Kocks JWH, Pavord ID, et al. An expert consensus framework for asthma remission as a treatment goal. J Allergy Clin Immunol. 2020;145(3):757\u201365. https:\/\/doi.org\/10.1016\/j.jaci.2019.12.006.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"3442_CR23","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1016\/j.jaip.2023.07.041","volume":"11","author":"GW Canonica","year":"2023","unstructured":"Canonica GW, Blasi F, Carpagnano GE, et al. Severe asthma network Italy definition of clinical remission in severe asthma: a Delphi consensus. J Allergy Clin Immunol Pract. 2023;11(12):3629\u201337.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"3442_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.opresp.2023.100277","volume":"5","author":"V Plaza Moral","year":"2023","unstructured":"Plaza Moral V, Alobid I, Alvarez Rodriguez C, et al. GEMA 5.3. Spanish guideline on the management of asthma. Open Respir Arch. 2023;5(4):100277.","journal-title":"Open Respir Arch"},{"issue":"3","key":"3442_CR25","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.resinv.2025.03.009","volume":"63","author":"J Tamaoki","year":"2025","unstructured":"Tamaoki J, Nagase H, Sano H, et al. Practical guidelines for asthma management (PGAM): digest edition. Respir Investig. 2025;63(3):405\u201321.","journal-title":"Respir Investig"},{"key":"3442_CR26","doi-asserted-by":"publisher","first-page":"1150162","DOI":"10.3389\/fimmu.2023.1150162","volume":"14","author":"I Pavord","year":"2023","unstructured":"Pavord I, Gardiner F, Heaney LG, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front Immunol. 2023;14:1150162.","journal-title":"Front Immunol"},{"issue":"1","key":"3442_CR27","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jaip.2024.10.009","volume":"13","author":"ID Pavord","year":"2025","unstructured":"Pavord ID, Rabe KF, Israel E, et al. Dupilumab induces long-term on-treatment clinical remission in patients with type 2 asthma. J Allergy Clin Immunol Pract. 2025;13(1):132\u201342.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"3442_CR28","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1007\/s12325-022-02098-1","volume":"39","author":"A Menzies-Gow","year":"2022","unstructured":"Menzies-Gow A, Hoyte FL, Price DB, et al. Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab. Adv Ther. 2022;39(5):2065\u201384.","journal-title":"Adv Ther"},{"issue":"S66","key":"3442_CR29","first-page":"2287","volume":"60","author":"M Castro","year":"2022","unstructured":"Castro M, Ambrose CS, Colice G, et al. On-treatment clinical remission with tezepelumab among patients with severe, uncontrolled asthma in the phase 3 NAVIGATOR study. Eur Respir J. 2022;60(S66):2287.","journal-title":"Eur Respir J"},{"issue":"3","key":"3442_CR30","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.3390\/ijms24032455","volume":"24","author":"A Maglio","year":"2023","unstructured":"Maglio A, Vitale C, Pelaia C, et al. Severe asthma remissions induced by biologics targeting IL5\/IL5r: results from a multicenter real-life study. Int J Mol Sci. 2023;24(3):2455.","journal-title":"Int J Mol Sci"},{"key":"3442_CR31","first-page":"A5985","volume":"207","author":"G Brusselle","year":"2023","unstructured":"Brusselle G, Lougheed MD, Canonica GW, et al. Clinical remission achievement in severe asthma following mepolizumab treatment: results from the REALITI-A study at 2 years. Am J Respir Crit Care Med. 2023;207:A5985.","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"3442_CR32","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.chest.2024.02.048","volume":"166","author":"D Thomas","year":"2024","unstructured":"Thomas D, McDonald VM, Stevens S, et al. Effect of azithromycin on asthma remission in adults with persistent uncontrolled asthma: a secondary analysis of a randomized, double-anonymized, placebo-controlled trial. Chest. 2024;166(2):262\u201370.","journal-title":"Chest"},{"issue":"2","key":"3442_CR33","doi-asserted-by":"publisher","first-page":"100431","DOI":"10.1016\/j.jacig.2025.100431","volume":"4","author":"M Ishizuka","year":"2025","unstructured":"Ishizuka M, Sugimoto N, Kobayashi K, et al. Clinical remission of mild-to-moderate asthma: rates, contributing factors, and stability. J Allergy Clin Immunol Glob. 2025;4(2):100431.","journal-title":"J Allergy Clin Immunol Glob"},{"issue":"7","key":"3442_CR34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","volume":"210","author":"L Perez-de-Llano","year":"2024","unstructured":"Perez-de-Llano L, Scelo G, Tran TN, et al. Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults. Am J Respir Crit Care Med. 2024;210(7):869\u201380.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3442_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2213-2600(24)00293-5","volume":"13","author":"A Shackleford","year":"2025","unstructured":"Shackleford A, Heaney LG, Redmond C, McDowell PJ, Busby J. Clinical remission attainment, definitions, and correlates among patients with severe asthma treated with biologics: a systematic review and meta-analysis. Lancet Respir Med. 2025;13(1):23\u201334.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"3442_CR36","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","volume":"9","author":"LA Lee","year":"2021","unstructured":"Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021;9(1):69\u201384.","journal-title":"Lancet Respir Med"},{"key":"3442_CR37","unstructured":"GSK. Trelegy Ellipta\u2014highlights of Prescribing Information. 2017. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Trelegy_Ellipta\/pdf\/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF. Accessed 13 February 2024."},{"issue":"2","key":"3442_CR38","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jaip.2024.10.037","volume":"13","author":"K Oishi","year":"2025","unstructured":"Oishi K, Hamada K, Fukatsu-Chikumoto A, et al. Clinical remission in patients with biologic-na\u00efve asthma: a multicenter study in Japan. J Allergy Clin Immunol Pract. 2025;13(2):328\u201332.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3442_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.waojou.2024.101016","volume":"18","author":"GW Canonica","year":"2025","unstructured":"Canonica GW, Blasi F, Paggiaro P, Heffler E, Braido F, Brussino L, et al. Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: evidence from the Severe Asthma Network in Italy (SANI). World Allergy Organ J. 2025;18(1):101016. https:\/\/doi.org\/10.1016\/j.waojou.2024.101016.","journal-title":"World Allergy Organ J"},{"issue":"2","key":"3442_CR40","doi-asserted-by":"publisher","first-page":"AB235","DOI":"10.1016\/j.jaci.2024.12.722","volume":"155","author":"M Hanslot","year":"2025","unstructured":"Hanslot M, Brusselle G, Papi A, et al. Achieving asthma remission with extrafine beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide (BDP\/FF\/GB) pMDI in adults with moderate-to-severe asthma: a post-hoc analysis of the TRIMARAN and TRIGGER Studies. J Allergy Clin Immunol. 2025;155(2):AB235.","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"3442_CR41","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","volume":"8","author":"HAM Kerstjens","year":"2020","unstructured":"Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000\u201312.","journal-title":"Lancet Respir Med"},{"issue":"10210","key":"3442_CR42","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","volume":"394","author":"JC Virchow","year":"2019","unstructured":"Virchow JC, Kuna P, Paggiaro P, Papi A, Singh D, Corre S, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737\u201349. https:\/\/doi.org\/10.1016\/S0140-6736(19)32215-9.","journal-title":"Lancet"},{"key":"3442_CR43","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.01333-2024","author":"A Mozaffaripour","year":"2025","unstructured":"Mozaffaripour A, Tcherner S, Durom E, et al. Airway mucus and 129Xe MRI ventilation after single-inhaler triple therapy in asthma. ERJ Open Res. 2025. https:\/\/doi.org\/10.1183\/23120541.01333-2024.","journal-title":"ERJ Open Res"},{"issue":"6","key":"3442_CR44","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1016\/j.chest.2023.01.037","volume":"163","author":"C Moermans","year":"2023","unstructured":"Moermans C, Brion C, Bock G, et al. Sputum type 2 markers could predict remission in severe asthma treated with anti-IL-5. Chest. 2023;163(6):1368\u201379.","journal-title":"Chest"},{"key":"3442_CR45","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00819-2023","author":"PJ McDowell","year":"2023","unstructured":"McDowell PJ, McDowell R, Busby J, et al. Clinical remission in severe asthma with biologic therapy: an analysis from the UK Severe Asthma Registry. Eur Respir J. 2023. https:\/\/doi.org\/10.1183\/13993003.00819-2023.","journal-title":"Eur Respir J"},{"issue":"5","key":"3442_CR46","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1164\/rccm.202412-2431VP","volume":"211","author":"A Bush","year":"2025","unstructured":"Bush A, Pavord ID. Stop the asthma treatment elevator, we need to get off! Am J Respir Crit Care Med. 2025;211(5):698\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"3442_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.anai.2024.09.023","volume":"134","author":"S Mailhot-Larouche","year":"2025","unstructured":"Mailhot-Larouche S, Celis-Preciado C, Heaney LG, Couillard S. Identifying super-responders: a review of the road to asthma remission. Ann Allergy Asthma Immunol. 2025;134(1):31\u201345. https:\/\/doi.org\/10.1016\/j.anai.2024.09.023.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"3442_CR48","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jaci.2017.04.009","volume":"141","author":"PW Sullivan","year":"2018","unstructured":"Sullivan PW, Ghushchyan VH, Globe G, Schatz M. Oral corticosteroid exposure and adverse effects in asthmatic patients. J Allergy Clin Immunol. 2018;141(1):110-6 e7.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"3442_CR49","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","volume":"201","author":"ER Bleecker","year":"2020","unstructured":"Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic literature review of systemic corticosteroid use for asthma management. Am J Respir Crit Care Med. 2020;201(3):276\u201393.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"3442_CR50","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jaip.2014.02.011","volume":"2","author":"AT Luskin","year":"2014","unstructured":"Luskin AT, Chipps BE, Rasouliyan L, et al. Impact of asthma exacerbations and asthma triggers on asthma-related quality of life in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol Pract. 2014;2(5):544-552e1-2.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3442_CR51","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12890-017-0409-3","volume":"17","author":"RY Suruki","year":"2017","unstructured":"Suruki RY, Daugherty JB, Boudiaf N, Albers FC. The frequency of asthma exacerbations and healthcare utilization in patients with asthma from the UK and USA. BMC Pulm Med. 2017;17(1):74.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"3442_CR52","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.jaip.2017.12.019","volume":"6","author":"H Ortega","year":"2018","unstructured":"Ortega H, Yancey SW, Keene ON, et al. Asthma exacerbations associated with lung function decline in patients with severe eosinophilic asthma. J Allergy Clin Immunol Pract. 2018;6(3):980-986e1.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"3442_CR53","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024. https:\/\/ginasthma.org\/2024-report\/. Accessed 14 May 2024."},{"issue":"4","key":"3442_CR54","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.jaip.2024.01.044","volume":"12","author":"WW Busse","year":"2024","unstructured":"Busse WW, Chupp G, Corbridge T, Stach-Klysh A, Oppenheimer J. Targeting asthma remission as the next therapeutic step toward improving disease control. J Allergy Clin Immunol Pract. 2024;12(4):894\u2013903. https:\/\/doi.org\/10.1016\/j.jaip.2024.01.044.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"3442_CR55","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.chest.2023.04.028","volume":"164","author":"NL Lugogo","year":"2023","unstructured":"Lugogo NL, Mohan A, Akuthota P, et al. Are we ready for asthma remission as a clinical outcome? Chest. 2023;164(4):831\u20134.","journal-title":"Chest"},{"issue":"5","key":"3442_CR56","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.anai.2021.08.096","volume":"127","author":"I Pavord","year":"2021","unstructured":"Pavord I, Busse W, Israel E, et al. Dupilumab leads to clinical asthma remission indicative of comprehensive improvement in patients with asthma. Ann Allergy Asthma Immunol. 2021;127(5):S33.","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"3442_CR57","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.rmed.2005.08.012","volume":"100","author":"EF Juniper","year":"2006","unstructured":"Juniper EF, Bousquet J, Abetz L, Bateman ED, Committee G. Identifying \u2018well-controlled\u2019 and \u2018not well-controlled\u2019 asthma using the asthma control questionnaire. Respir Med. 2006;100(4):616\u201321. https:\/\/doi.org\/10.1016\/j.rmed.2005.08.012.","journal-title":"Respir Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03442-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03442-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03442-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:02:59Z","timestamp":1771268579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03442-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,24]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["3442"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03442-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,24]]},"assertion":[{"value":"20 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"John Oppenheimer has served on adjudication committees or data and safety monitoring boards for AstraZeneca, GSK, Novartis, and Sanofi-Regeneron; received consultancy fees from AstraZeneca, GSK, and Sanofi; and received grants and personal fees from GSK. Ian D Pavord has received speaker\u2019s fees, payments for organizing education events, honoraria for attending advisory panels, sponsorship to attend international scientific meetings, research grants, or payments to support FDA approval meetings from Aerocrine, Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, GSK, Knopp, Merck, Novartis, Roche-Genentech, Sanofi-Regeneron, and Teva; acted as an expert witness for a patent dispute involving AstraZeneca and Teva; is a co-patent holder for the Leicester Cough Questionnaire, and received payments for use of the Leicester Cough Questionnaire in clinical trials from Bayer, Insmed, and Merck. Tom Corbridge, Jodie Crawford, Steven Gould, Mohamed Hamouda, Peter Howarth, Emmeline Burrows, Alison Moore, Stephen G Noorduyn, David Slade, and Stephen Weng are employed by GSK and hold financial equities in GSK. Stephen G Noorduyn is a PhD candidate at McMaster University, Hamilton, ON, Canada. Njira Lugogo has received consulting fees from Amgen, AstraZeneca, Avillion, Genentech, GSK, Niox, Novartis, Regeneron, Sanofi, and Teva; honoraria for non-speaker\u2019s bureau presentations from GSK and AstraZeneca; and travel support from AstraZeneca; her institution received research support from Amgen, AstraZeneca, Avillion, Evidera, Genentech, Gossamer Bio, GSK, Janssen, Novartis, Regeneron, Sanofi, and Teva. She is an honorary faculty member of the Observational and Pragmatic Research Institute (OPRI) but does not receive compensation for this role\n                      .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"CAPTAIN was performed in accordance with the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice, and applicable country-specific regulatory requirements, and received United States central ethics approval from the Chesapeake Institutional Review Board (now Advarra; IRB: 00000971, IORG: 0000635). This was a multinational, multicenter study; a full list of the ethics committees that approved the study are included in Table\n                      \n                      . Written informed consent was obtained from all patients before participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}}]}}